>MNTA – That would explain no request for this data from Teva or Amphastar.<
Amphastar got the same FDA letter about immunogenicity concerns that Sandoz/MNTA got, according to WPI’s CEO on the Credit Suisse webcast two days ago. He said Teva got the same letter too, although he didn’t disclose how he knows that. Regards, Dew
Market Data 
Markets 
AI
